1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.

2 trials

Sponsors

Saitama Breast Cancer Clinical Study Group (SBCCSG), Dept of surgical oncology, Hiroshima university hospital

Conditions

Breast Cancer

Phase 2

Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who presented well-defined taxane resistance

Active, not recruitingJPRN-UMIN000006965

Saitama Breast Cancer Clinical Study Group (SBCCSG)Breast Cancer

Start: 2012-01-01Target: 52Updated: 2026-06-29

Safety trial of eriburin treatment to patient who has peripheral neuropathy

Active, not recruitingJPRN-UMIN000008802

Dept of surgical oncology, Hiroshima university hospitalBreast Cancer

Start: 2012-09-01Target: 48Updated: 2026-06-29